1582-4934/asset/olbannerleft.gif?v=1&s=9ac4fbc1c8dd6b354380356601e09fc12424db35)
1582-4934/asset/olbannerright.gif?v=1&s=cd3126c456d5857b7dbedcf7ab88bbd934f98dcc)
You have open access to this content
Transcriptional regulation of survivin by c-Myc in BCR/ABL-transformed cells: implications in anti-leukaemic strategy
Article first published online: 13 OCT 2008
DOI: 10.1111/j.1582-4934.2008.00549.x
© 2008 The Authors Journal compilation © 2009 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
Total views since August 2010: 61
Additional Information
How to Cite
Fang, Z. H., Dong, C. L., Chen, Z., Zhou, B., Liu, N., Lan, H. F., Liang, L., Liao, W. B., Zhang, L. and Han, Z. C. (2009), Transcriptional regulation of survivin by c-Myc in BCR/ABL-transformed cells: implications in anti-leukaemic strategy. Journal of Cellular and Molecular Medicine, 13: 2039–2052. doi: 10.1111/j.1582-4934.2008.00549.x
Publication History
- Issue published online: 26 NOV 2009
- Article first published online: 13 OCT 2008
- Received: March 8, 2008; Accepted: October 2, 2008
- Abstract
- Article
- References
- Cited By
- Cumulative Usage
References
- 1, . Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer. 2007; 7: 441–53.
- 2, , . The molecular biology of chronic myeloid leukemia. Blood. 2000; 96: 3343–56.
- 3. Bcr-Abl and inhibition of apoptosis in chronic myelogenous leukemia cells. Apoptosis. 2000; 5: 315–8.
- 4, , , et al . Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL. J Exp Med. 2000; 191: 977–84.
- 5, . Bcr/Abl activates transcription of the Bcl-X gene through STAT5. Blood. 2000; 96: 2269–76.
- 6, , , et al . Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood. 2005; 105: 3303–11.
- 7, , , et al . Complementary functions of the antiapoptotic protein A1 and serine/ threonine kinase pim-1 in the BCR/ABL-mediated leukemogenesis. Blood. 2002; 99: 4531–9.
- 8, , , et al . Identification of heme oxygenase-1 as a novel BCR/ABL-dependent survival factor in chronic myeloid leukemia. Cancer Res. 2004; 64: 3148–54.
- 9, , , et al . Bcr-Abl signaling through the PI-3/S6 kinase pathway inhibits nuclear translocation of the transcription factor Bach2, which represses the antiapoptotic factor heme oxygenase-1. Blood. 2007; 109: 1211–9.
- 10, , , et al . Deregulation of the Wilms’ tumour gene 1 protein (WT1) by BCR/ABL1 mediates resistance to imatinib in human leukaemia cells. Leukemia. 2007; 21: 2485–94.
- 11, , , et al . Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylate. Exp Hematol. 2003; 31: 1073–80.
- 12, , , et al . Expression of apoptosis proteins in chronic myelogenous leukemia: associations and significance. Cancer. 2001; 91: 1964–72.
- 13. Validating survivin as a cancer therapeutic target. Nat Rev Cancer. 2003; 3: 46–54.
- 14. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer. 2008; 8: 61–70.
- 15, . Survivin and leukemia. Int J Hematol. 2004; 80: 232–8.
- 16, , , et al . Expression of the antiapoptotic gene survivin in chronic myeloid leukemia. Anticancer Res. 2003; 23: 589–92.
- 17, , , et al . Survivin expression in the progression of chronic myeloid leukemia: a sequential study in 16 patients. Leuk Lymphoma. 2005; 46: 717–22.
- 18, , , et al . Quantitative analysis of the anti-apoptotic gene survivin expression in malignant haematopoietic cells. Anticancer Res. 2001; 21: 595–600.
- 19, , , et al . Disruption of the inhibitor of apoptosis protein survivin sensitizes Bcr-abl-positive cells to STI571-induced apoptosis. Cancer Res. 2005; 65: 8224–32.
- 20, , , et al . Regulation of survivin expression through Bcr-Abl/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells. Blood. 2006; 107: 1555–63.
- 21, , , et al . G-CSF-mobilized peripheral blood mononuclear cells from diabetic patients augment neovascularization in ischemic limbs but with impaired capability. J Thromb Haemost. 2006; 4: 993–1002.
- 22, , , et al . Enhanced growth suppression of Philadephia1 leukemia cells by targeting bcr3/abl2 and VEGF through antisense strategy. Leukemia. 2005; 19: 1517–24.
- 23, , . Cell division and cell survival in the absence of survivin. Proc Natl Acad Sci USA. 2004; 101: 15100–5.
- 24, , , et al . Expression of the miR-17–92 polycistron in chronic myeloid leukemia (CML) CD34+ cells. Blood. 2007; 109: 4399–405.
- 25, , , et al . STAT5 activation by BCR-Abl contributes to transformation of K562 leukemia cells. Blood. 1999; 94: 1108–12.
- 26, , , et al . Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. J Cell Sci. 2002; 115: 575–85.
- 27, , , et al . Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest. 2004; 114: 1117–27.
- 28, , , et al . Nuclear export is essential for the tumor-promoting activity of survivin. FASEB J. 2007; 21: 207–16.
- 29, , , et al . Imatinib mesylate (STI571) decreases the vascular endothelial growth factor plasma concentration in patients with chronic myeloid leukemia. Blood. 2004; 104: 495–501.
- 30, , . Growth factor-dependent regulation of survivin by c-myc in human breast cancer. J Mol Endocrinol. 2006; 37: 377–90.
- 31, , , et al . Jak2 is involved in c-Myc induction by Bcr-Abl. Oncogene. 2002; 21: 7137–46.
- 32, , , et al . Nuclear or cytoplasmic expression of survivin: what is the significance Int J Cancer. 2005; 114: 509–12.
- 33, , , et al . Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression. J Biol Chem. 2006; 281: 25903–14.
- 34, , , et al . A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation. Blood. 2006; 107: 2507–16.
- 35, , , et al . Janus kinase 2: a critical target in chronic myelogenous leukemia. Cancer Res. 2006; 66: 6468–72.
- 36, , , et al . Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation. Oncogene. 2001; 20: 6188–95.
- 37, , , et al . Survivin and molecular pathogenesis of colorectal cancer. Lancet. 2003; 362: 205–9.
- 38, , , et al . Differential roles for the coactivators CBP and p300 on TCF/beta-catenin-mediated survivin gene expression. Oncogene. 2005; 24: 3619–31.
- 39, , , et al . Contribution of STAT3 to the activation of survivin by GM-CSF in CD34+ cell lines. Exp Hematol. 2007; 35: 957–66.
- 40, , , et al . Aberrant regulation of survivin by the RB/E2F family of proteins. J Biol Chem. 2004; 279: 40511–20.
- 41, , , et al . Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem. 2002; 277: 3247–57.
- 42, , , et al . KLF5 interacts with p53 in regulating survivin expression in acute lymphoblastic leukemia. J Biol Chem. 2006; 281: 14711–8.
- 43, . Transcriptional analysis of human survivin gene expression. Biochem J. 1999; 344: 305–11.
- 44, , , et al . BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood. 2002; 100: 3767–75.
- 45, . The cancer antiapoptosis mouse survivin gene: characterization of locus and transcriptional requirements of basal and cell cycle-dependent expression. Cancer Res. 1999; 59: 3143–51.
- 46, , , et al . Transcriptional activation of survivin through the NF-kappaB pathway by human T-cell leukemia virus type I tax. Int J Cancer. 2005; 115: 967–74.
- 47. Disentangling the MYC web. Proc Natl Acad Sci USA. 2002; 99: 5757–9.
- 48, , . Dominant negative MYC blocks transformation by ABL oncogenes. Cell. 1992; 70: 901–10.
- 49, , , et al . c-Myc-regulated microRNAs modulate E2F1 expression. Nature. 2005; 435: 839–43.
- 50, , , et al . Crystal structure and mutagenic analysis of the inhibitor-of-apoptosis protein survivin. Mol Cell. 2000; 6: 173–82.
- 51, , , et al . Improved low molecular weight Myc-Max inhibitors. Mol Cancer Ther. 2007; 6: 2399–408.
- 52, , , et al . Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation. Blood. 2007; 109: 2147–55.